FDG-PET/CT's power for staging and restaging breast cancer is attracting attention. It could also detect recurrence in more than two-thirds of these patients and change the management plan in up to a third, according to German investigators.
FDG-PET/CT's power for staging and restaging breast cancer is attracting attention. It could also detect recurrence in more than two-thirds of these patients and change the management plan in up to a third, according to German investigators.
Dr. Michael Souvatzoglou and colleagues in the nuclear medicine department at the Technical University of Munich prospectively enrolled 118 patients with suspicion of breast cancer recurrence based on elevated tumor markers, clinical signs, and abnormal standard imaging studies. PET/CT identified local and metastatic disease in 79 cases.
Follow-up data on 87 patients showed that a change in therapeutic management was made for 29 patients (33%) based on PET/CT findings. Changes included initiation of chemotherapy in 14, initiation of radiotherapy in 12, and initiation of chemoradiotherapy in three. Souvatzoglou presented his group's results at the 2008 SNM.
Five Insights on Artifacts and Limitations with Contrast-Enhanced Mammography
February 29th 2024Noting that technique issues, patient positioning miscues and atypical features can all contribute to faulty interpretation with contrast-enhanced mammography (CEM), researchers at the European Congress of Radiology shared their insights on navigating artifacts and limitations with CEM.
Moving Beyond Mammography for Screening and Staging of Invasive Lobular Carcinoma
February 16th 2024For women with dense breasts, only 25 percent of breast radiologists are confident in the use of mammography for diagnosing invasive lobular carcinoma, according to newly published survey results from the Society of Breast Imaging.